Hansson L, Hedner T
Department of Medicine, University of Göteborg, Ostra Hospital, Sweden.
J Cardiovasc Pharmacol. 1987;10 Suppl 3:S39-44.
The rationale for ketanserin therapy in hypertension is reviewed against the background of known physiological and pathophysiological effects of serotonin. The usefulness of the serotonin (5-HT2) antagonist ketanserin in the treatment of hypertension is evaluated with respect to its known antihypertensive property as well as in relation to its effect on hypertension-induced cardiovascular changes, platelet hyperreactivity, and atheroma formation. Based on ketanserin's documented antihypertensive effect and also on its potentially positive effect on cardiovascular mortality via other mechanisms, it would appear that ketanserin could offer a highly rational approach to the treatment of hypertension and its risks in the future.
在血清素已知的生理和病理生理作用背景下，对酮色林治疗高血压的基本原理进行了综述。就血清素（5-HT2）拮抗剂酮色林已知的降压特性以及其对高血压引起的心血管变化、血小板高反应性和动脉粥样硬化形成的影响而言，评估了其在高血压治疗中的效用。基于酮色林已记录的降压作用以及其通过其他机制对心血管死亡率的潜在积极作用，酮色林似乎可为未来高血压及其风险的治疗提供一种高度合理的方法。
